Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that predictable routine of meetings, deadlines, and what-not has returned. It is unavoidable, after all. Our coping mechanism, as you know, is to fire up the coffee kettle and prepare some cups of stimulation. Why not join us? No prescription is required, which also means no hassles with the health insurer. Meanwhile, here are some items of interest, which you may also find stimulating. Hope your day goes well and please do keep in touch …

Four former Food and Drug Administration commissioners are expressing opposition to congressional “right to try” legislation, just as Republican House leaders prepare to bring a bill up for another vote a week after it failed to pass, The Washington Post reports. “There is no evidence that either bill would meaningfully improve access for patients, but both would remove the FDA from the process and create a dangerous precedent that would erode protections for vulnerable patients,” they say.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy